The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global hemoglobinopathies market was valued at US$ 8.36 Billion in 2021.
We expect the global hemoglobinopathies market to exhibit a CAGR of 9.50% during 2022-2027.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective hemoglobinopathies treatment through blood transfusion procedure to mitigate the risk of coronavirus infection upon hospital visits.
The high prevalence of chronic blood-related medical conditions, such as Sickle Cell Disease (SCD) and thalassemia, along with the rising awareness towards wide presence of hemoglobinopathies treatment solutions, is primarily driving the global hemoglobinopathies market.
Based on the type, the global hemoglobinopathies market has been segregated into thalassemia, sickle cell disease, and others. Currently, sickle cell disease holds the largest market share.
Based on the treatment, the global hemoglobinopathies market can be bifurcated into blood transfusion, stem-cell transplantation, analgesics, antibiotics, ACE inhibitors, hydroxyurea, and others. Among these, blood transfusion treatment currently represents the majority of the total market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global hemoglobinopathies market include Bio-Rad Laboratories Inc., bluebird bio Inc., Bristol-Myers Squibb Company, Danaher Corporation, Emmaus Life Sciences Inc., Gamida-Cell Ltd., Global Blood Therapeutics Inc., Novartis AG, PerkinElmer Inc., Pfizer Inc., Prolong Pharmaceuticals LLC, Sangamo Therapeutics Inc., and Sysmex Corporation.
Home Healthcare Market by Product (Therapeutic Products, Testing, Screening, and Monitoring Products, Mobility Care Products), Service (Skilled Nursing, Rehabilitation Therapy, Hospice & Palliative Care, Unskilled Care, Respiratory Therapy, Infusion Therapy, Pregnancy Care), Indication (Cancer, Respiratory Diseases, Movement Disorders, Cardiovascular Diseases & Hypertension, Pregnancy, Wound Care, Diabetes, Hearing Disorders, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at